Psychoactive Drugs Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Psychoactive Drugs stocks.

Psychoactive Drugs Stocks Recent News

Date Stock Title
May 1 FLGC Flora Growth Corp. Applauds Reported Historic DEA Move to Reschedule Cannabis
May 1 ZVRA Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024
May 1 MATV Axalta Coating Systems (AXTA) Tops Q1 Earnings and Revenue Estimates
Apr 30 MAPS Cannabis Stocks React To DEA Rescheduling: Canopy & Aurora Surge, Tilray, WM Tech Hold Steady
Apr 30 MAPS 2024 Winners Unveiled for "Best of Weedmaps" Program
Apr 30 AQST Analysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for
Apr 29 AQST Aquestive stock falls amid Libervant approval, Anaphylm update
Apr 29 CMPS Psychedelic drug developers could benefit from NIH funding for chronic pain
Apr 29 FLGC Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Apr 29 ZVRA Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024
Apr 29 AQST Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
Apr 29 CMPS Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
Apr 27 AQST Aquestive wins FDA approval for anti-seizure therapy Libervant
Apr 26 INDV Why Indivior PLC (LON:INDV) Looks Like A Quality Company
Apr 25 INDV Indivior PLC (INDV) Q1 2024 Earnings Call Transcript
Apr 25 CMPS COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?
Apr 25 AQST Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
Apr 25 MATV Mativ Holdings, Inc.'s (NYSE:MATV) Intrinsic Value Is Potentially 58% Above Its Share Price
Apr 25 INDV Indivior PLC (INDV) Q1 Earnings and Revenues Lag Estimates
Apr 25 FLGC Insiders Re-Evaluate Their US$1.0m Stock Purchase As Flora Growth Falls To US$22m
Psychoactive Drugs

A psychoactive drug, psychopharmaceutical, or psychotropic is a chemical substance that changes brain function and results in alterations in perception, mood, consciousness, cognition, or behavior. These substances may be used medically; recreationally; to purposefully improve performance or alter one's consciousness; as entheogens; for ritual, spiritual, or shamanic purposes; or for research. Some categories of psychoactive drugs, which have therapeutic value, are prescribed by physicians and other healthcare practitioners. Examples include anesthetics, analgesics, anticonvulsant and antiparkinsonian drugs as well as medications used to treat neuropsychiatric disorders, such as antidepressants, anxiolytics, antipsychotics, and stimulant medications. Some psychoactive substances may be used in the detoxification and rehabilitation programs for persons dependent on or addicted to other psychoactive drugs.
Psychoactive substances often bring about subjective (although these may be objectively observed) changes in consciousness and mood that the user may find rewarding and pleasant (e.g., euphoria or a sense of relaxation) or advantageous (e.g. increased alertness) and are thus reinforcing. Substances which are both rewarding and positively reinforcing have the potential to induce a state of addiction – compulsive drug use despite negative consequences. In addition, sustained use of some substances may produce physical or psychological dependence or both, associated with somatic or psychological-emotional withdrawal states respectively. Drug rehabilitation attempts to reduce addiction, through a combination of psychotherapy, support groups, and other psychoactive substances. Conversely, certain psychoactive drugs may be so unpleasant that the person will never use the substance again. This is especially true of certain deliriants (e.g. Jimson weed), powerful dissociatives (e.g. Salvia divinorum), and classic psychedelics (e.g. LSD, psilocybin), in the form of a "bad trip".
Psychoactive drug misuse, dependence and addiction have resulted in legal measures and moral debate. Governmental controls on manufacture, supply and prescription attempt to reduce problematic medical drug use. Ethical concerns have also been raised about over-use of these drugs clinically, and about their marketing by manufacturers. Popular campaigns to allow certain recreational drug use (e.g. cannabis) are also ongoing.

Browse All Tags